Evaluating tamoxifen effect in the prevention of hypertrophic scars following surgical incisions.
To evaluate the clinical utility of tamoxifen in the prevention of hypertrophic scars (HTSs). In a double-blind randomized clinical trial, 300 patients with a history of HTSs who underwent surgery with different skin incisions were assigned randomly to two groups. The first received tamoxifen tablets postoperatively according to a standard protocol, and the control group received placebo. After 2 months, the two groups were compared according to the development of HTSs, and the results were analyzed. The studied population comprised 235 men (78.7%) and 65 women (21.7%) who developed HTSs after surgical incision, 138 of whom (92%) were in the study group and 78 (52%) in the control group. Tamoxifen seems to be an effective agent in the prevention of HTSs after surgery.